Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 27;13(4):583.
doi: 10.3390/jpm13040583.

Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV

Baptiste Sellem  1   2 , Basma Abdi  2   3 , Minh Lê  4 , Roland Tubiana  1   2 , Marc-Antoine Valantin  1   2 , Sophie Seang  1   2 , Luminita Schneider  1   2 , Antoine Fayçal  1 , Gilles Peytavin  5 , Cathia Soulié  2   3 , Anne-Geneviève Marcelin  2   3 , Christine Katlama  1   2 , Valérie Pourcher  1   2 , Romain Palich  1   2
Affiliations

Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV

Baptiste Sellem et al. J Pers Med. .

Abstract

In this observational study, we aimed to evaluate whether bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) administered 5 or 4 days a week is able to maintain viral suppression in people living with HIV (PLHIV). We enrolled 85 patients who initiated intermittent B/F/TAF between 28 November 2018 and 30 July 2020: median (IQR) age 52 years (46-59), duration of virological suppression 9 years (3-13), CD4 633/mm3 (461-781). Median follow-up was 101 weeks (82-111). The virological success rate (no virological failure [VF]: confirmed plasma viral load [pVL] ≥ 50 copies/mL, or single pVL ≥ 200 copies/mL, or ≥50 copies/mL with ART change) was 100% (95%CI 95.8-100) and the strategy success rate (pVL < 50 copies/mL with no ART regimen change) was 92.9% (95%CI 85.3-97.4) at W48. Two VF occurred at W49 and W70, in 2 patients self-reporting poor compliance. No resistance mutation emerged at time of VF. Eight patients presented strategy discontinuation for adverse events. There was no significant change in the CD4 count, residual viraemia rate, neither body weight during follow-up, but a slight increase in CD4/CD8 ratio (p = 0.02). In conclusion, our findings suggest that B/F/TAF administered 5 or 4 days a week could maintain the control of HIV replication in virologically suppressed PLHIV while reducing cumulative exposition of ART.

Keywords: HIV; antiretroviral therapy; intermittent; people living with HIV.

PubMed Disclaimer

Conflict of interest statement

G.P., R.T., M.-A.V., S.S., L.S., M.L., C.S., A.-G.M., C.K., V.P. and R.P. have received travel grants and advisory fees from Gilead, ViiV Healthcare and Merck. B.S., A.F., and B.A. have no conflicts of interest to declare. A.-G.M. declares a conflict of interest with Theratec.

Figures

Figure 1
Figure 1
Virological success rate (A) and strategy success rate (B) under intermittent B/F/TAF over time.
See this image and copyright information in PMC

References

    1. Cohen C.J., Colson A.E., Sheble-Hall A.G., McLaughlin K.A., Morse G.D. Pilot Study of a Novel Short-Cycle Antiretroviral Treatment Interruption Strategy: 48-Week Results of the Five-Days-on, Two-Days-off (FOTO) Study. HIV Clin. Trials. 2007;8:19–23. doi: 10.1310/hct0801-19. - DOI - PubMed
    1. de Truchis P., Assoumou L., Landman R., Mathez D., Le Dû D., Bellet J., Amat K., Katlama C., Gras G., Bouchaud O., et al. Four-Days-a-Week Antiretroviral Maintenance Therapy in Virologically Controlled HIV-1-Infected Adults: The ANRS 162-4D Trial. J. Antimicrob. Chemother. 2018;73:738–747. doi: 10.1093/jac/dkx434. - DOI - PubMed
    1. Turkova A., Moore C.L., Butler K., Compagnucci A., Saïdi Y., Musiime V., Nanduudu A., Kaudha E., Cressey T.R., Chalermpantmetagul S., et al. Weekends-off Efavirenz-Based Antiretroviral Therapy in HIV-Infected Children, Adolescents and Young Adults (BREATHER): Extended Follow-up Results of a Randomised, Open-Label, Non-Inferiority Trial. PLoS ONE. 2018;13:e0196239. doi: 10.1371/journal.pone.0196239. - DOI - PMC - PubMed
    1. Landman R., de Truchis P., Assoumou L., Lambert S., Bellet J., Amat K., Lefebvre B., Allavena C., Katlama C., Yazdanpanah Y., et al. A 4-Days-on and 3-Days-off Maintenance Treatment Strategy for Adults with HIV-1 (ANRS 170 QUATUOR): A Randomised, Open-Label, Multicentre, Parallel, Non-Inferiority Trial. Lancet HIV. 2022;9:e79–e90. doi: 10.1016/S2352-3018(21)00300-3. - DOI - PubMed
    1. Pugliese P., Cuzin L., Cabié A., Poizot-Martin I., Allavena C., Duvivier C., El Guedj M., de la Tribonnière X., Valantin M.A., Dellamonica P., et al. A Large French Prospective Cohort of HIV-Infected Patients: The Nadis Cohort. HIV Med. 2009;10:504–511. doi: 10.1111/j.1468-1293.2009.00719.x. - DOI - PubMed